抗肺癌新药开发和临床应用项目.docVIP

抗肺癌新药开发和临床应用项目 ■??项目简介 ??项目背景：吉林省肺癌药物研究所所长刘洪吉教授经多年探索、创新及大量的临床试验，研制出具有国际先进水平的抗肺癌新药肺积消。在临床试验的基础上，基本具备规模化生产和临床应用的条件。 ??生产规模：年产12万人份的抗肺癌药品500万盒和建筑面积为5000平方米建筑面积的临床医院及必要设备。 ??合作方式：合资、合作?、技术转让 ??项目总投资：4500万元 ??需外方投资内容：现汇 ??建设地点：九台市西道口南侧 ??占地面积及建筑面积：占地面积15000平方米，建筑面积5000万平方米 ??预计经济效益：实现销售收入24096万元，利润7229万元 ??预计投资利润率：300%，回收期1.4年（含建设期1年） ??项目进展情况：长春市计委项目建议书批复，有临床使用制剂批号，目前正在申办国家准字药品号。 ■??中方概况 ??企业名称：吉林省肺癌药物研究所 ??法定地址：吉林省九台市西环路56号 ??法定代表人：刘洪吉 ??所有制形式：民营? 企业概况：注册资本50万元，现有人员6人，高级职员3人，中级职员3人 ??可为项目提供的建设和生产条件：土地、厂房、肺积消抗癌药生产技术配方。? ??通讯地址：吉林省九台市外经局 ??邮????编：130500 ??项目联系人：??刘洪吉 ??联系电话：0431-?2325304? Project of Innovation and Clinic Application for New Medicine of Anti Lung Cancer Brief introduction for project Project background: The new medicine of anti lung cancer “ Feijixiao” with advanced international technology, was developed by professor Liu Hongji, the director from Jilin Province Lung Cancer Medicine Research Institute through his exploration in many years and on base of great deal of clinic test. “Feijixiao” now has been in the situation for production with scale and clinic application basing on clinic test. Production scale: Yearly output of 5 million boxes for application of 120 thousands of persons. Clinic hospital is necessarily equipped with construction area of 5000 m2. Cooperation form: Joint Venture, cooperation and knowhow transfer. Total investment for project: 45 million Yuan Foreign investment: spot exchange Location of construction: South side of Xidaokou , Jiutai Land and building area: Land area: 15000 m2 Building area: 5000 m2 Estimated economical benefit: Income from sales: 240,960,000 Yuan Profit: 72,290,000 Yuan Estimated investment profit ratio: 300% with reclaim period of 1.4 year (including 1 year construction period) Project process: Letter of project suggestion has been approved by Changchun City Planning Committee with clinic applicable preparation lot no. Applying for state approval medicine no. General introduction for Chinese party Name of